Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
50 participants
INTERVENTIONAL
2006-08-31
2008-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients
NCT00420771
Feasibility of Early Gabapentin as an Intervention for Neurorecovery
NCT05302999
Gabapentin's Effects on Insomnia in Patients With Recent Concussion
NCT01421264
Chronic Low Back Pain Research Project
NCT00108550
Abuse Liability of Pregabalin and Its Effects on Benzodiazepine Withdrawal Symptoms
NCT02423018
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gabapentin
1200 mg/daily of Gabapentin
Gabapentin
Placebo
1200mg/d of Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Placebo
Gabapentin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meets DSM-IV-TR criteria for Cannabis Dependence
* Smoked marijuana at least once a week in the 90 days prior to study participation
* Willing to attend 12 weekly study visits and 1 follow-up visit
Exclusion Criteria
* Significant medical disorders that will increase potential risk or interfere with study participation
* Women with childbearing potential who are pregnant, nursing, or refuse to use a reliable method of birth control
* Treatment with an investigational drug in the last month
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
The Scripps Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Barbara J. Mason
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Barbara J. Mason, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
The Scripps Research Institute- Pearson Center for Alcoholism and Addiction Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Scripps Research Institute
La Jolla, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, Buffkins K, Kyle M, Adusumalli M, Begovic A, Rao S. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology. 2012 Jun;37(7):1689-98. doi: 10.1038/npp.2012.14. Epub 2012 Feb 29.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DA020766-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.